Clinical Trials on Locally Advanced Head and Neck Squamous Cell Carcinoma in France

Total 663 results

European Organisation for Research and Treatment...
Merck KGaA, Darmstadt, Germany

Recruiting

Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (RAVINA)

Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Belgium, Netherlands, Norway, United Kingdom, Ireland, Italy, Slovenia, Germany, Spain
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, Italy, Canada, Korea, Republic of, United Kingdom, Germany, Vietnam, Japan, France, India, Taiwan, Thailand, Malaysia, Turkey, Brazil, Belgium, Poland, Austria, Hungary
Nanobiotix

Recruiting

NBTXR3 With or Without Cetuximab in LA-HNSCC

Aged | Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Spain, Israel, United States, Taiwan, Finland, Japan, Belgium, Korea, Republic of, Hungary, China, Georgia, Portugal, Austria, Bulgaria, Canada, Czechia, Germany, Greece, Romania, Serbia
Hoffmann-La Roche

Terminated

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
Replimune Inc.
Bristol-Myers Squibb

Withdrawn

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Squamous Cell Carcinoma of Head and Neck | Recurrent Head and Neck Squamous Cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, United Kingdom, Czechia, France, Germany, Greece, Poland
Ascendis Pharma Oncology Division A/S

Recruiting

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor | Locally Advanced Solid Tumor | Neoadjuvant Melanoma | Head and Neck Squamous Cell Carcinoma HNSCC | HPV-associated Cancers | Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)

United States, Australia, Spain, Netherlands, Korea, Republic of, Taiwan
Assistance Publique - Hôpitaux de Paris
National Cancer Institute (NCI); Canceropôle Ile de France

Completed

Comprehensive Geriatric Assessment and Head and Neck Elderly Cancer Patients (EGéSOR)

Head and Neck Squamous Cell Carcinomas (HNSCCs)

France
European Organisation for Research and Treatment...
Danish Head and Neck Cancer Group

Active, not recruiting

AF CRT +/- Nimorazole in HNSCC

Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers

Belgium, France, Poland, Australia, Germany, Netherlands, Switzerland
National Cancer Institute (NCI)

Terminated

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Locally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell Carcinoma

United States
University Hospital, Montpellier
National Cancer Institute, France

Unknown

Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma (CIRCUTEC)

Metastatic Head-and-neck Squamous-cell Carcinoma

France
Centre Antoine Lacassagne
GERCOR - Multidisciplinary Oncology Cooperative Group; GORTEC

Withdrawn

Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) (PICH)

Head and Neck Squamous Cell Carcinoma (HNSCC)

France
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Patients With Head and Neck Cancer. (ProNiHN)

Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck

France
Sanofi

Completed

Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

France
Centre Henri Becquerel

Unknown

Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma (PERSO-NECK)

Head and Neck Squamous Cell Carcinoma

France
AbbVie
Idera Pharmaceuticals, Inc.

Completed

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Advanced Solid Tumors Cancer

United States, France, Germany, Israel, Netherlands, Spain
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Unknown

Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma (MEDINDUCTION)

Head and Neck Cancers

France
Institut du Cancer de Montpellier - Val d'Aurelle

Active, not recruiting

Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer (SIMPA01)

Head and Neck Squamous Cell Carcinoma

France
Institut de cancérologie Strasbourg Europe
Institut National de la Santé Et de la Recherche Médicale, France; Centre National...

Recruiting

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma (IPRICE)

Head and Neck Cancer

France
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC (ELAN-RT)

Head and Neck Squamous Cell Carcinoma

France, Monaco
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma (ADJORL1)

Head and Neck Squamous Cell Carcinoma

France
AstraZeneca
MedImmune LLC

Active, not recruiting

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Spain, United States, Belgium, Germany, United Kingdom, Italy
Centre Leon Berard

Not yet recruiting

Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO) (TACO)

Oral Squamous Cell Carcinomas

France
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Active, not recruiting

Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma (SURVEILL'ORL)

Head and Neck Squamous Cell Carcinoma

France
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (PembroRad)

Squamous Cell Carcinoma of the Head and Neck

France
Rennes University Hospital

Completed

One-step Nucleic Acid Amplification for Detecting Lymph Node Metastasis of Head and Neck Squamous Cell Carcinoma (OSNA-ORL)

cN0 Oral Squamous Cell Carcinomas

France
Institut de cancérologie Strasbourg Europe
Hôpitaux Universitaires de Strasbourg

Recruiting

Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) (OPPIDOM)

Squamous Cell Carcinoma of Head and Neck | Oropharyngeal Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

France
Hoffmann-La Roche

Completed

A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

Spain, France, United Kingdom, Netherlands, Italy
Merck KGaA, Darmstadt, Germany

Terminated

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

France
Groupe Oncologie Radiotherapie Tete et Cou

Active, not recruiting

Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC (OMET)

Head and Neck Squamous Cell Carcinoma

France
AstraZeneca

Completed

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Head and Neck Squamous Cell Carcinoma

Taiwan, United States, France
Centre Leon Berard

Terminated

A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC (UMBRELLA)

Head and Neck Squamous Cell Carcinoma (HNSCC) | Premalignant Lesion

France
Centre Hospitalier Universitaire, Amiens

Not yet recruiting

Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers (NIVOCHIMLOC)

Squamous Cell Carcinoma of the Head and Neck | Paclitaxel | Nivolumab | Carboplatin

France
Cytovation AS
Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst)

Advanced Breast Cancer | Advanced Melanoma | Advanced Head and Neck Squamous Cell Carcinoma

United States, France, Italy, Spain, Netherlands
Centre Jean Perrin
Groupement Inter-Régional de Recherche Clinique et d'Innovation Auvergne...

Recruiting

Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer (NeckTAR)

Locally Advanced Head and Neck Carcinoma

France
Central Hospital, Nancy, France

Unknown

Anti-tumor Specific Immune Response in Head and Neck Cancers (CORISAT)

Head and Neck Squamous Cell Carcinoma

France
Groupe Oncologie Radiotherapie Tete et Cou

Recruiting

Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (XXL_2022-01)

Squamous Cell Carcinoma of the Head and Neck

France
CHU de Reims

Completed

Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot Study (ORODIFF)

Head and Neck Squamous Cell Carcinoma

France
Exicure, Inc.

Terminated

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Merkel Cell Carcinoma | Advanced or Metastatic Cutaneous Squamous Cell Carcinoma | Advanced or Metastatic Melanoma | Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

United States
Centre Leon Berard

Active, not recruiting

Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (ATHENA)

Head and Neck Neoplasms

France
Groupe Oncologie Radiotherapie Tete et Cou
For Drug Consulting; Eurofins

Recruiting

A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP)

Squamous Cell Carcinoma of Head and Neck

France
Pierre Fabre Medicament

Completed

Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer

Recurrent or Metastatic Head and Neck Carcinoma

France
University Hospital, Caen

Completed

Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection (TEPVAD)

Squamous Cell Carcinoma of the Head and Neck

France
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion (CisFRad)

Squamous Cell Carcinoma of the Head and Neck

France
UNICANCER

Terminated

Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (COPAN-ORL06)

Carcinoma, Squamous Cell of Head and Neck

France
UNICANCER

Completed

Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients (PREDICTOR)

Carcinoma, Squamous Cell of Head and Neck

France
Inhibrx, Inc.

Recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
University Hospital, Caen

Completed

Nutrition and Life QUality Patients With Head and Neck Cancers (NUQUE2)

Squamous Cell Carcinoma of the Head and Neck

France
Institut Claudius Regaud
AstraZeneca

Completed

Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial. (CITHARE)

Oropharyngeal Squamous Cell Carcinoma

France
Exelixis

Recruiting

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305)

Head and Neck Squamous Cell Carcinoma

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Squamous Cell Carcinoma of the Head and Neck

France, United States, Israel, Korea, Republic of, Australia

Clinical Trials on Locally Advanced Head and Neck Squamous Cell Carcinoma in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations